Aspirin for the Prevention of Preeclampsia and Pregnancy Outcomes After Assisted Reproductive Technology

• Status: Not yet recruiting
• Trial end date: 2026-05-01
• Target enrollment: 0
• Participant gender: Female

Summary

This study seeks to validate the hypothesis that nulliparous pregnant women after Assisted Reproductive Technology (ART) are at high risk of preeclampsia and perinatal complications and represent a subgroup for which aspirin prophylaxis during pregnancy may be effective in the prevention of preterm preeclampsia and other perinatal adverse outcomes.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Toulouse
• Treatments: Aspirin

Criteria

Inclusion Criteria:

• Nulliparous women aged 18 years or more

• Pregnancy following ART, including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), oocyte donation or intrauterine insemination with sperm donor

• Singleton pregnancy

• Evolutive pregnancy between 9 and 14 weeks of gestation

• Women affiliated to a French Social Security Insurance or equivalent social protection

• Written informed consent

Exclusion Criteria:

• Major fetal abnormality

• Regular treatment with aspirin (including antiphospholipid syndrome)

• Aspirin contraindications (allergy, von Willebrand disease, peptic ulceration, hemophilia)

• Women protected by law.

• Women included in another interventional study.